An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.
about
Brodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsIxekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsSevere infectious diseases of childhood as monogenic inborn errors of immunityApplications of Next-generation Sequencing in Systemic Autoimmune DiseasesInterleukin 17-Mediated Host Defense against Candida albicansIL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicansPrimary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestationsMendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunityDiscovery of single-gene inborn errors of immunity by next generation sequencingOropharyngeal Candidiasis in HIV Infection: Analysis of Impaired Mucosal Immune Response to Candida albicans in Mice Expressing the HIV-1 TransgeneMendelian genetics of human susceptibility to fungal infectionThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingHuman TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndromeThe differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signalingOral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections.IL-17 in severe asthma. Where do we stand?Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.The mycobiota: interactions between commensal fungi and the host immune system.CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans.Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kindSignaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis.Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasisC/EBPβ Promotes Immunity to Oral Candidiasis through Regulation of β-Defensins.Inborn errors in immunity: unique natural models to dissect oral immunity.When the Fight against Fungi Goes WrongA Candida albicans Strain Expressing Mammalian Interleukin-17A Results in Early Control of Fungal Growth during Disseminated Infection.Neutrophils Do Not Express IL-17A in the Context of Acute Oropharyngeal Candidiasis.Adaptive immune responses to Candida albicans infection.Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome.IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or bothWhole-exome sequencing to analyze population structure, parental inbreeding, and familial linkage.Skin Immunity to Candida albicans.Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis.Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency.Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency.Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity.Role of neutrophils in IL-17-dependent immunity to mucosal candidiasis.Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis.
P2860
Q26746100-76CAD745-C4A3-44A5-8471-B525942EFF4DQ26766567-960B2D84-3017-404F-B2A4-AAE8C7B171B2Q26775891-536866EA-E7E6-40DC-894D-1C93E10D6B90Q26782546-4AAB3648-1823-4A9A-A94C-EE6AAF3FC0E1Q26798127-AA64ECAC-18FE-450A-A4BE-E04750D4C4C0Q26799351-32F17BF3-F34B-49A2-B052-8824D28C4BF7Q26830870-970BEF2F-31A5-415C-A26B-D1D683987DBEQ26862947-F5762DC4-9741-4613-8252-FB1E249214ABQ27003187-CD39C78D-1161-4ABD-A35A-B42F5856D2BEQ27005798-C5278CBB-81B6-4E99-BB8B-0C92DA76A5D2Q27022250-23C190EB-4A74-4CFD-BF2F-C9FCDA5F7B84Q27687800-18BA1CA3-47D4-4D1F-84AF-547401995EF9Q28266613-1C25CA99-1672-41AF-BEAA-E64FA4B87E7BQ33992530-331E3DD6-C066-4E27-8F97-DD00E502EF09Q34230506-1AFA5FBF-9F17-4331-8620-448B439D3291Q34435370-BC6B8E7D-6A28-40A4-950A-CD8D9FDF6BECQ34523567-9EFC2592-412F-4AAC-B49E-087832A6C65CQ35096262-CBE414D6-66E2-44C9-9568-5F6F797D31CFQ35098244-98934C5B-4419-48E3-BC35-F5AEA15AB838Q35190461-0EADFBD1-EF32-400B-83D1-0728C26F8A10Q35301398-3BA70F41-65DC-4B3D-BFBD-74B8B8C59B95Q35568424-FA3BD3C5-5B22-40C7-8AEE-475703278F0CQ35758463-EDF4CBA9-6849-4E81-9D80-43DEB50B637AQ35797001-1432A9E0-5D2B-4BBA-BD56-140CA7C3E7C2Q35914364-26C8247E-DC75-4609-97E1-A71315EF2E2FQ35947439-1B8583F4-AB42-4880-A87E-FB171F2BEC57Q36096377-CBA1333F-C779-4B8A-98DE-B86EF290BFABQ36147114-4ECD6E44-B688-4AF6-AF22-3ABE61FCEE7BQ36264301-AAE44F2D-955A-448A-9594-EBDB7AF5D707Q36344921-AFB07146-FAA1-4661-9C56-80FFEDB97B0CQ36480090-13CF14F6-3E2D-48DA-A93D-A10A89C85E8CQ36797990-7E227142-EAFD-46C0-AA75-A7B04435B6A1Q37021842-C516483C-827E-4D66-B3F2-55865EB0518AQ37062344-A9ED9C3F-C739-4263-8CDF-1A638DD70382Q37111268-E67A52DB-151D-4BA2-B111-D0154A8CA8FCQ37411703-69A31681-80C8-4F40-8F2C-B1047B4F541DQ37534176-3A033AC8-189F-48F0-8C9B-1F809D6BCD76Q37538514-4A35586E-B2D2-4F3A-B10C-12E0F291A423Q37624083-033C077F-139E-48B6-9C63-F341C30C76E7Q37643893-5976FD0F-E327-4E6E-AB62-FA1E8143DB7F
P2860
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@en
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@nl
type
label
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@en
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@nl
prefLabel
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@en
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@nl
P2093
P2860
P50
P1433
P1476
An ACT1 mutation selectively a ...... nic mucocutaneous candidiasis.
@en
P2093
Aziz Belkadi
Chenhui Wang
Claire Fieschi
Michel Rybojad
Sophie Cypowyj
Vincent Pedergnana
Xiaoxia Li
P2860
P304
P356
10.1016/J.IMMUNI.2013.09.002
P407
P577
2013-10-10T00:00:00Z